

6 January 2026

Treatment of Asthma

1. How many patients have been treated (for any condition) in the last 4 months with:

Adult Respiratory Service:

- **Benralizumab** 137
- **Dupilumab** 58
- **Omalizumab** 24
- **Reslizumab** <5
- **Mepolizumab** 267
- **Tezepelumab** 124

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

Paediatric Respiratory Service:

- **Mepolizumab** <5
- **Dupilumab** 5
- **Tezepelumab** <5

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

Combined Adult and Paediatric Respiratory Response:

- **Age 6-11** <5
- **Age 12-17** 7
- **Age 18 and above** 612

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

Adult Respiratory Service:

- **Dupilumab** 58
- **Omalizumab** 24

6 January 2026

Paediatric Respiratory Service:

- **Dupilumab** 5
- **Omalizumab** 0

4. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with:

- **Dupilumab**
- **Mepolizumab**

Adult Respiratory Service:

There are currently no patients within Belfast Trust receiving biologics for COPD.

We have a few patients who are primarily Asthma, with an overlap diagnosis of COPD but we do not hold these figures separately and therefore we are unable to answer this question.

Paediatric Respiratory Service:

N/A - COPD is not a paediatric condition.